Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Robert Negrin to Stanford University
    • Trial status: Active, Not Recruiting to Completed
    • Enrollment target: estimated 20 to confirmed 21
    • Study description expanded, about 8 words
    v13
  2. Lead sponsor: Stanford University to Robert Negrinv12 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Interventions: infusion of activated T cells (Genetic) to Cytokine Induced Killer Cells (Drug)
    • Site details revised
    • Study arms: 0 to 1
  3. Site contact updatedv11
  4. Re-verified, no change to tracked fieldsv10
  5. Primary and study completion dates: Dec 2012
    • Eligibility criteria revised
    • Secondary endpoints revised (3)
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Eligibility criteria revised
    • Site contact updated
    v8
  2. Start date: Jan 2004 to Jun 2004
    • Study site revised
    • Eligibility criteria shortened, about 2 words
    v7
  3. Collaborators expanded, about 5 wordsv6
  4. Study completion date: Apr 2004 to not stated
    • Study description shortened, about 22 words
    • Eligibility criteria expanded, about 2 words
    v5
  5. 3 versions Re-verified since Mar 27, 2006, no change to tracked fieldsv2-v4
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 1 dose escalation study evaluating the use of activated T-cells to treat relapsed malignancy (cancer) following allogeneic hematopoietic cell transplantation, without causing GvHD.
Trial Details
NCT Number NCT00185757
Lead Sponsor Stanford University
Collaborators: National Institutes of Health (NIH)
Conditions
(from sponsor)		 Multiple Myeloma, Blood and Marrow Transplant (BMT)
Related terms Multiple Myeloma
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov